Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ: INCY )

67.71 UNCHANGED
Streaming Delayed Price Updated: 3:04 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Incyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results comparable to adults at 52 weeks. 
Via Benzinga
Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps
Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary endpoint fell short. 
Via Benzinga
These S&P500 stocks are moving in today's pre-market session
The US market session of Friday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
What Analysts Are Saying About Incyte Stock
Via Benzinga
Insights into Incyte Q4 Earnings
Via Benzinga
What's going on in today's session: S&P500 gap up and gap down stocks
Stay tuned for the market movements in the S&P500 index on Monday. Check out the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced. 
Via Chartmill
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for. 
Via StockStory
What's going on in today's pre-market session: S&P500 movers
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
NASDAQ:INCY, an undervalued stock with good fundamentals.
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
Via Benzinga
Why Incyte (INCY) Shares Are Plunging Today
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.9% in the morning session after the company reported fourth-quarter results with full-year guidance for key products such as... 
Via StockStory
Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday?
Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Gapping S&P500 stocks in Monday's session
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches
Incyte projects 2025 Jakafi revenue of $2.925B-$2.975B, up 4.76%-6.55%, and Opzelura sales of $630M-$670M, reflecting up to 31.81% growth. 
Via Benzinga
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2024, with sales up 16.3% year on year to $1.18 billion. Its non-GAAP profit of $1.43 per share... 
Via StockStory
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect. 
Via StockStory
Promising Signs: INCYTE CORP Setting the Stage for a Breakout.
Exploring INCYTE CORP's Technical Signals and Breakout Potential: Based on good technical signals, INCYTE CORP is potentially setting up for a breakout. 
Via Chartmill
Earnings Scheduled For February 10, 2025
Via Benzinga
Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents.
Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced. 
Via Chartmill
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline
Incyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets. 
Via Benzinga
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool
Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?
Large-cap stocks had a rough week, including Target, PDD Holdings, ZTO Express, Tenet Healthcare, Ulta Beauty, Intuit, Nokia, Alibaba, Santander, and Incyte. 
Via Benzinga
Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review
Many leaders flashed buy signals. Bitcoin raced toward $100,000. 
Via Investor's Business Daily
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Nasdaq Reverses Losses Amid Nvidia Fanfare
Stocks are attempting to walk back this morning's losses tied to escalating tensions between Russia and Ukraine. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.